Skip to main content
Clinical Trials/NL-OMON37661
NL-OMON37661Not yet recruitingNot Applicable

The identification and spatial distribution of different nutrient receptors along the gastrointestinal tract - Identification of nutrient receptors GI tract

niversiteit Maastricht0 sites50 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
50

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • •Inclusion criteria for duodenal biopsies:
  • •- Step 1 (patients asked for participation):
  • •1) Patients (male and female between 18 and 65 years) referred for upper GI endoscopy (because of functional complaints)
  • •2) Based on medical history and previous examination, no objection arises for taking extra biopsies during the gastroduodenoscopy.;- Step 2 (patients agreed to participate and in who biopsies will be taken)
  • •1) Patients with no relevant endoscopic abnormalities (gastroduodenoscopy): patients without gastric or duodenal ulcers/polyps/lesions suspect for malignancy and esophageal lesions or varices.;Inclusion criteria for ileal and colon biopsies:
  • •- Step 1 (patients asked for participation):
  • •1) Patients (male and female between 18 and 65 years) referred for colonoscopy (because of screening for colorectal cancer or follow up of colonic polyps)
  • •2) Based on medical history and previous examination, no objection arises for taking extra biopsies during the colonoscopy;- Step 2 (patients agreed to participate and in who biopsies will be taken)
  • •1) Patients with no relevant endoscopic abnormalities (colonoscopy): patients without ileal and/or colonic ulcers/polyps/diverticula and lesions suspect for malignancy

Exclusion Criteria

  • •Exclusion criteria for duodenal, ileal and colon biopsies:
  • •1) History of severe cardiovascular, gastrointestinal/ hepatic, hematological/immunologic, metabolic/nutritional disease and/or laboratory assessments which might limit participation in the study. The severity of the disease (major interference with the execution of the experiment or potential influence on the study outcomes) will be decided by the principal investigator.
  • •2) Use of medication, which could interfere with normal coagulation (anticoagulants, antiplatelet drugs).
  • •3) Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgement of the principle investigator)
  • •4) Excessive alcohol consumption (>20 alcoholic consumptions per week)

Investigators

Similar Trials